Table 1.

Summary of approved BTKIs [5,14,20,75,76,77,78].

Name	Synonyms	Type of Inhibitor	Indications	Year of Approval	Activity (IC50)
Ibrutinib Imbruvica®	CRA-032765 PC-32765 PCI-32765 PCI-32765-00	Irreversible	MCL, CLL, SLL, WM, MZL, GVHD	2013	BTK IC50 = 0.47 nM
					ITK IC50 = 55 nM
					TEC IC50 = 3.2 nM
Acalabrutinib Calquence®	ACP-196	Irreversible	CLL, SLL, MCL	2017	BTK IC50 = 2.5 nM
					ITK IC50 > 20,000 nM
					TEC IC50 = 37 nM
Zanubrutinib Brukinsa®	BGB-3111	Irreversible	NHL, CLL, MCL	2019	BTK IC50 = 0.3 nM
					ITK IC50 = 56 nM
					TEC IC50 = 2 nM
Tirabrutinib Velexbru®	ONO-4059	Irreversible	CNS lymphoma, WM, CLL	2020	BTK IC50 = 6.8 nM
					ITK IC50 > 20,000 nM
					TEC IC50 = 48 nM
Orelabrutinib	ICP-022	Irreversible	MCL, CLL, SLL	2020	BTK IC50 = 1.6 nM